ReviewFrontiers in cardiovascular medicine2026
Orosomucoid 2 (ORM2) in type 2 diabetes and coronary artery disease: a potential link between insulin resistance and vascular inflammation.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are closely linked cardiometabolic disorders that share common inflammatory, metabolic, and vascular mechanisms. However, the molecular mediators underlying their interconnected pathophysiology remain incompletely understood. Orosomucoid 2 (ORM2), a hepatocyte-derived acute-phase glycoprotein, has emerged as a potential mediator at the interface of metabolic and vascular dysfunction. Experimental and clinical evidence suggests that ORM2 plays important roles in hepatic lipid metabolism, insulin sensitivity, and immune regulation. Reduced ORM2 expression has been reported in obesity and insulin-resistant states, while circulating orosomucoid levels have been associated with diabetic nephropathy, microalbuminuria, and long-term risk of myocardial infarction. Mechanistically, ORM2 suppresses hepatic
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.